Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7463520 | 0.87 | PKM (0.40) | PKMSMN1; SMN2CYP3A4NPSR1ALDH1A1 | |
| SCHEMBL3779761 | 0.85 | CYP3A4 (0.38) | PKMSMN1; SMN2CYP3A4NPSR1ALDH1A1 | |
| SCHEMBL7460913 | 0.81 | SNCA (0.47) | CYP3A4ALDH1A1TSHRHSD17B10CA12 | |
| SCHEMBL17386357 | 0.80 | CYP3A4 (0.50) | PKMSMN1; SMN2CYP3A4NPSR1ALDH1A1 | |
| SCHEMBL7833842 | 0.79 | CYP4F2 (0.49) | SMN1; SMN2ALDH1A1KDM4ELMNAMAPK1 | |
| SCHEMBL7826173 | 0.79 | CA1 (0.38) | PKMSMN1; SMN2CYP3A4ALDH1A1TSHR | |
| SCHEMBL8701436 | 0.77 | CYP1A2 (0.33) | SMN1; SMN2CYP1A2CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL9634242 | 0.75 | CNR2 (0.43) | SMN1; SMN2CYP1A2CYP2C9CYP3A4NPSR1 | |
| SCHEMBL29620611 | 0.75 | CYP3A4 (0.46) | PKMSMN1; SMN2CYP3A4NPSR1ALDH1A1 | |
| SCHEMBL3783318 | 0.75 | CA12 (0.59) | SMN1; SMN2ALDH1A1LMNAPOLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | ASUBIO PHARMA CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-7618977-B2 | Method of treating dermatitis comprising administering a chymase inhibitor | ASUBIO PHARMA CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1142586-B1 | USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7169951-B2 | Quinazoline derivatives and pharmaceutical applications thereof | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2007-01-30 | — | — | US | disclosed |
| EP-1174151-B1 | THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1192950-B1 | THERAPEUTIC DRUGS FOR DERMATITIS EXHIBITING A BIPHASIC SKIN REACTION CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1114035-B1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | DAIICHI ASUBIO PHARMA CO LTD (JP) | 2006-05-17 | — | — | EP | disclosed |
| CN-1245979-C | Medicine for preventing and treating dermatitis containing chymase inhibitor as active ingredient | DAIICHI ASBIAO PHARMACEUTICAL (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1245978-C | Preventive and therapeutic agent for various diseases associated with eosinophilia comprising chymase inhibitor as active ingredient | DAIICHI ASBIAO PHARMACEUTICAL (JP) | 2006-03-22 | — | — | CN | disclosed |
| US-6921766-B1 | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-07-26 | — | — | US | disclosed |
| EP-1192949-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR FIBROSIS CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1192950-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR DERMATITISES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-1174151-A1 | PREVENTIVE OR THERAPEUTIC DRUGS FOR VARIOUS EOSINOPHILIA-RELATED DISEASES CONTAINING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT | SUNTORY LIMITED (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1142586-A1 | INHIBITORS AGAINST VASCULAR LIPID DEPOSITION CONTAINING CHYMASE-INHIBITING SUBSTANCES | SUNTORY LIMITED (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1114035-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNTORY LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| EP-0721944-B1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LTD (JP) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000010982-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEROF | SUNTORY LIMITED (JP) | 2000-03-02 | — | — | WO | disclosed |
| US-5814631-A | CHYMASE INHIBITOR, CARDIVASCULAR | SUNTORY LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| US-5691335-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0721944-A1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LIMITED (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029695-A1 | METHOD OF TREATING DERMATITIS COMPRISING ADMINISTERING A CHYMASE INHIBITOR | CMA1, DNPEP, SERPINB1 | PKM 4400/4885SMN1; SMN2 3818/4885CYP1A2 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.